AU2009326993B2 - Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug - Google Patents

Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug Download PDF

Info

Publication number
AU2009326993B2
AU2009326993B2 AU2009326993A AU2009326993A AU2009326993B2 AU 2009326993 B2 AU2009326993 B2 AU 2009326993B2 AU 2009326993 A AU2009326993 A AU 2009326993A AU 2009326993 A AU2009326993 A AU 2009326993A AU 2009326993 B2 AU2009326993 B2 AU 2009326993B2
Authority
AU
Australia
Prior art keywords
treatment
fatty acids
ohod
pathologies
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2009326993A
Other languages
English (en)
Other versions
AU2009326993A1 (en
Inventor
Rafael Alvarez Martinez
Gerardo Avila Martin
Gwendolyn Barcelo Coblijn
Juana Barcelo Estarellas
Xavier Busquets Xaubet
Pablo Vicente Escriba Ruiz
Victoria Llado Canellas
Daniel Lopez
Julian Taylor Green
Silvia Teres Jimenez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009326993(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Publication of AU2009326993A1 publication Critical patent/AU2009326993A1/en
Application granted granted Critical
Publication of AU2009326993B2 publication Critical patent/AU2009326993B2/en
Priority to AU2016228171A priority Critical patent/AU2016228171A1/en
Priority to AU2016228167A priority patent/AU2016228167A1/en
Priority to AU2018229472A priority patent/AU2018229472B2/en
Priority to AU2018229474A priority patent/AU2018229474B2/en
Priority to AU2019222955A priority patent/AU2019222955B2/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
AU2009326993A 2008-12-09 2009-12-04 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug Revoked AU2009326993B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2016228171A AU2016228171A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2016228167A AU2016228167A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229472A AU2018229472B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229474A AU2018229474B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2019222955A AU2019222955B2 (en) 2008-12-09 2019-08-30 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ESP200803480 2008-12-09
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2016228167A Division AU2016228167A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2016228171A Division AU2016228171A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Publications (2)

Publication Number Publication Date
AU2009326993A1 AU2009326993A1 (en) 2011-07-07
AU2009326993B2 true AU2009326993B2 (en) 2016-06-16

Family

ID=42242375

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2009326993A Revoked AU2009326993B2 (en) 2008-12-09 2009-12-04 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2016228171A Abandoned AU2016228171A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2016228167A Abandoned AU2016228167A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229474A Active AU2018229474B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229472A Active AU2018229472B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2019222955A Active AU2019222955B2 (en) 2008-12-09 2019-08-30 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2016228171A Abandoned AU2016228171A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2016228167A Abandoned AU2016228167A1 (en) 2008-12-09 2016-09-13 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229474A Active AU2018229474B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2018229472A Active AU2018229472B2 (en) 2008-12-09 2018-09-12 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
AU2019222955A Active AU2019222955B2 (en) 2008-12-09 2019-08-30 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Country Status (18)

Country Link
US (3) US9000042B2 (OSRAM)
EP (4) EP2842555B1 (OSRAM)
JP (2) JP5711140B2 (OSRAM)
KR (1) KR101683643B1 (OSRAM)
CN (1) CN102355897B (OSRAM)
AU (6) AU2009326993B2 (OSRAM)
BR (1) BRPI0922870A8 (OSRAM)
CA (1) CA2745052C (OSRAM)
DK (3) DK3366285T3 (OSRAM)
ES (5) ES2342997B1 (OSRAM)
HU (2) HUE037396T2 (OSRAM)
IL (1) IL213354A (OSRAM)
MX (1) MX2011005978A (OSRAM)
PL (3) PL3366285T3 (OSRAM)
PT (4) PT2374453E (OSRAM)
RU (1) RU2531353C2 (OSRAM)
SI (1) SI3366285T1 (OSRAM)
WO (1) WO2010066931A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) * 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
RU2679443C2 (ru) * 2014-10-21 2019-02-11 Университат Де Лес Ильес Балеарс Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
AU2021212330A1 (en) * 2020-01-29 2022-09-22 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872141A (en) * 1971-08-03 1975-03-18 Ciba Geigy Corp 1-Alkoxycarboxylic acid derivatives for the regulation of plant growth
WO2003062244A1 (en) * 2002-01-22 2003-07-31 Syngenta Participations Ag Phenyl substituted heterocyclic compounds useful as herbicides
US20040053789A1 (en) * 2000-08-07 2004-03-18 Jones Timothy Gareth John Surfactant
EP1435235A1 (en) * 2001-10-11 2004-07-07 Universitat de les Illes Balears Use of hydroxyoleic acid and similar compounds in the production of medicaments

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (OSRAM) * 1969-10-27 1974-07-24
US3931306A (en) * 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) * 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
AU1926592A (en) * 1991-04-10 1992-11-17 Eugene J. Van Scott Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
DE69833791D1 (de) * 1997-11-24 2006-05-04 Scripps Research Inst Hemmer der "gap junction communication"
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
KR20150080004A (ko) * 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
US20120252967A1 (en) 2008-04-18 2012-10-04 Grains Research And Development Corporation Polyurethanes
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872141A (en) * 1971-08-03 1975-03-18 Ciba Geigy Corp 1-Alkoxycarboxylic acid derivatives for the regulation of plant growth
US20040053789A1 (en) * 2000-08-07 2004-03-18 Jones Timothy Gareth John Surfactant
EP1435235A1 (en) * 2001-10-11 2004-07-07 Universitat de les Illes Balears Use of hydroxyoleic acid and similar compounds in the production of medicaments
WO2003062244A1 (en) * 2002-01-22 2003-07-31 Syngenta Participations Ag Phenyl substituted heterocyclic compounds useful as herbicides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEMANY, R., et al., Hypertension, 2004, vol. 43, pages 249-254 *
CARBALLEIRA, N.M., et al., J. Nat. Prod., 1998, vol. 61, pp. 1543-1546 *
CHEN, W., et al., J. Biomed. Mater. Res. (Appl. Biomater.), 1997, vol. 38, pages 43-48 *
LLADO, V., et al., Abstracts / Chemistry and Physics of Lipids, 149S (2007) S74-S91, at S84 PO 141 *
MAGRIOTI, V., et al., Lipids, 2002, vol. 37, pp. 223-228 *
MARKIDIS, T., et al., Anticancer Research, 2001, vol. 21, pages 2835-2840 *
MARTINEZ, J., et al., Mol. Pharmacol., 2005, vol. 67, pages 531-540 *
PADRON, J.M., et al., Tetrahedron: Asymmetry, 1998, vol. 9, pp. 3381-3394 *

Also Published As

Publication number Publication date
AU2016228167A1 (en) 2016-09-29
EP2842556A2 (en) 2015-03-04
BRPI0922870A2 (pt) 2016-01-12
RU2531353C2 (ru) 2014-10-20
EP2374453A1 (en) 2011-10-12
WO2010066931A4 (es) 2010-08-05
US20110294883A1 (en) 2011-12-01
AU2009326993A1 (en) 2011-07-07
IL213354A0 (en) 2011-07-31
US9000042B2 (en) 2015-04-07
ES2535498T3 (es) 2015-05-12
ES2535498T8 (es) 2016-08-19
CA2745052C (en) 2017-11-07
CN102355897A (zh) 2012-02-15
CA2745052A1 (en) 2010-06-17
WO2010066931A1 (es) 2010-06-17
US9730906B2 (en) 2017-08-15
PL2842556T3 (pl) 2018-07-31
US10588883B2 (en) 2020-03-17
EP2842555A3 (en) 2015-04-15
EP2842556A3 (en) 2015-08-05
AU2019222955A1 (en) 2019-09-19
EP2842556B1 (en) 2018-01-31
IL213354A (en) 2017-06-29
EP3366285A1 (en) 2018-08-29
EP2842555A2 (en) 2015-03-04
EP3366285B1 (en) 2021-06-30
HUE037396T2 (hu) 2018-08-28
KR20110126100A (ko) 2011-11-22
AU2018229474A1 (en) 2018-10-04
ES2899274T3 (es) 2022-03-10
JP2012511510A (ja) 2012-05-24
DK2842556T3 (en) 2018-03-26
DK2374453T3 (en) 2015-03-30
HUE056170T2 (hu) 2022-01-28
ES2673406T3 (es) 2018-06-21
CN102355897B (zh) 2014-06-04
AU2018229474B2 (en) 2019-08-22
ES2342997B1 (es) 2011-06-06
AU2016228171A1 (en) 2016-09-29
US20180193297A1 (en) 2018-07-12
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
BRPI0922870A8 (pt) 2017-12-26
SI3366285T1 (sl) 2021-11-30
EP2842555B1 (en) 2018-04-18
JP2015061856A (ja) 2015-04-02
MX2011005978A (es) 2011-10-11
PL2374453T3 (pl) 2015-07-31
AU2019222955B2 (en) 2020-11-05
AU2018229472A1 (en) 2018-10-04
EP2374453B1 (en) 2015-02-18
ES2661412T3 (es) 2018-03-28
DK3366285T3 (da) 2021-10-04
PT2842555T (pt) 2018-07-06
ES2342997A1 (es) 2010-07-20
JP5711140B2 (ja) 2015-04-30
RU2011128335A (ru) 2013-01-20
AU2018229472B2 (en) 2019-07-18
PL3366285T3 (pl) 2022-01-10
US20150297548A1 (en) 2015-10-22
KR101683643B1 (ko) 2016-12-07
PT3366285T (pt) 2021-10-07
EP2374453A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
US10588883B2 (en) Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines
US11253497B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent

Effective date: 20210708